{"id":"mrna-1273","safety":{"commonSideEffects":[{"rate":"~70","effect":"Injection site pain"},{"rate":"~60","effect":"Fatigue"},{"rate":"~55","effect":"Headache"},{"rate":"~40","effect":"Myalgia"},{"rate":"~15","effect":"Fever"},{"rate":"~35","effect":"Chills"}]},"_chembl":null,"_fixedAt":"2026-03-30T18:14:50.751201","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine delivers synthetic mRNA wrapped in lipid nanoparticles into host cells, where it is translated into spike protein. This protein is presented to the immune system, stimulating both CD8+ T-cell and B-cell responses, including production of neutralizing antibodies against SARS-CoV-2. The mRNA is subsequently degraded through normal cellular pathways.","oneSentence":"mRNA-1273 is a lipid nanoparticle-formulated messenger RNA vaccine that encodes the SARS-CoV-2 spike protein, instructing cells to produce the antigen and trigger adaptive immune responses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:56:02.776Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"COVID-19 prevention in adults and pediatric populations"},{"name":"COVID-19 booster vaccination"}]},"_fixedFields":["pubmed(2280)"],"trialDetails":[{"nctId":"NCT06585241","phase":"PHASE4","title":"A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations","status":"RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2024-09-09","conditions":"SARS-CoV-2","enrollment":1144},{"nctId":"NCT05212610","phase":"PHASE4","title":"Assessing Safety of Coronavirus Infection (COVID-19) Messenger RNA (mRNA) Vaccine Administration in the Setting of a Previous Adverse Reaction","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2022-03-21","conditions":"COVID-19, Corona Virus Infection","enrollment":137},{"nctId":"NCT05392075","phase":"","title":"COVID-19 Breakthrough Infection in Fully Vaccinated People and in People Who Received a Booster Dose","status":"COMPLETED","sponsor":"Methodist Health System","startDate":"2023-03-15","conditions":"COVID-19 Pneumonia, COVID-19","enrollment":100},{"nctId":"NCT07279766","phase":"PHASE4","title":"Effectiveness of mRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adults Aged 50-64 Years Without Risk Factors for Severe COVID-19","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tor Biering-Sørensen","startDate":"2025-12-11","conditions":"COVID-19","enrollment":285000},{"nctId":"NCT07266558","phase":"PHASE4","title":"A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)","status":"RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2025-11-26","conditions":"SARS-CoV-2","enrollment":30000},{"nctId":"NCT05397223","phase":"PHASE1","title":"A Study of Modified mRNA Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-05-24","conditions":"SARS-CoV-2, Seasonal Influenza, Respiratory Syncytial Virus","enrollment":308},{"nctId":"NCT07408297","phase":"PHASE2","title":"Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda","status":"COMPLETED","sponsor":"Victoria Biomedical Research Institute","startDate":"2022-05-18","conditions":"COVID -19, SARS CoV 2 Infection","enrollment":1919},{"nctId":"NCT05119855","phase":"PHASE3","title":"Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-03-28","conditions":"Papillomavirus Infections, Coronavirus Disease (COVID-19)","enrollment":165},{"nctId":"NCT05077254","phase":"PHASE2","title":"COVID Protection After Transplant-Immunosuppression Reduction","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-12-06","conditions":"Kidney Transplant Recipients, Liver Transplant Recipients","enrollment":48},{"nctId":"NCT05658523","phase":"PHASE3","title":"COVID-19 Booster Study in Healthy Adults in Australia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Murdoch Childrens Research Institute","startDate":"2023-02-28","conditions":"COVID-19","enrollment":496},{"nctId":"NCT06694389","phase":"PHASE3","title":"Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ≥50 Years of Age","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2024-11-18","conditions":"COVID-19, Influenza","enrollment":2457},{"nctId":"NCT05584202","phase":"PHASE2","title":"Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants","status":"TERMINATED","sponsor":"ModernaTX, Inc.","startDate":"2022-09-30","conditions":"SARS-CoV-2","enrollment":68},{"nctId":"NCT05168813","phase":"PHASE2, PHASE3","title":"Efficacy Study of COVID-19 mRNA Vaccine in Regions With SARS-CoV-2 Variants of Concern","status":"COMPLETED","sponsor":"COVID-19 Prevention Network","startDate":"2021-12-01","conditions":"SARS-CoV-2 Infection, HIV Infections, COVID-19","enrollment":14237},{"nctId":"NCT05436834","phase":"PHASE3","title":"A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-06-21","conditions":"SARS-CoV-2","enrollment":1807},{"nctId":"NCT05289037","phase":"PHASE2","title":"COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-03-30","conditions":"COVID-19","enrollment":1270},{"nctId":"NCT04852978","phase":"PHASE2","title":"COVID-19 Study to Assess Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2021-04-29","conditions":"Healthy, Chronic Stable Illness","enrollment":295},{"nctId":"NCT05556720","phase":"PHASE3","title":"Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Monash University","startDate":"2022-12-01","conditions":"HIV, Organ Transplantation, Lymphoma, Non-Hodgkin","enrollment":960},{"nctId":"NCT04649151","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2020-12-09","conditions":"SARS-CoV-2","enrollment":4328},{"nctId":"NCT04969276","phase":"PHASE2","title":"Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2021-07-16","conditions":"Influenza Immunization, Healthy Volunteers","enrollment":306},{"nctId":"NCT06038617","phase":"PHASE4","title":"Safety of Simultaneous mRNA COVID-19 Vaccine With Other Childhood Vaccines in Young Children","status":"COMPLETED","sponsor":"Duke University","startDate":"2023-10-30","conditions":"Fever After Vaccination, Fever, Seizures Fever","enrollment":344},{"nctId":"NCT05000216","phase":"PHASE2","title":"COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-08-13","conditions":"Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris","enrollment":258},{"nctId":"NCT04761822","phase":"PHASE2","title":"COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-04-07","conditions":"SARS-CoV Infection, COVID-19, Allergic Reaction","enrollment":746},{"nctId":"NCT06189053","phase":"","title":"A Study to Assess Long-term Outcomes of Myocarditis Following Administration of COVID-19 mRNA Vaccine (SPIKEVAX)","status":"ACTIVE_NOT_RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2022-04-30","conditions":"Myocarditis","enrollment":1500},{"nctId":"NCT06113692","phase":"","title":"A Study on the Clinical Course, Outcomes and Risk Factors of Myocarditis and Pericarditis After Moderna COVID-19 Vaccine","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2023-03-31","conditions":"Myocarditis, Pericarditis","enrollment":1169},{"nctId":"NCT04969263","phase":"PHASE2","title":"COVID-19 Protection After Transplant Pilot Study","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-08-10","conditions":"Kidney Transplant Recipients","enrollment":81},{"nctId":"NCT04848584","phase":"","title":"Pfizer-BioNTech COVID-19 Vaccine Effectiveness Study - Kaiser Permanente Southern California","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-05-15","conditions":"COVID-19","enrollment":1},{"nctId":"NCT05158140","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-01-12","conditions":"Pneumococcal Infection","enrollment":850},{"nctId":"NCT05137236","phase":"PHASE2","title":"A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Vaccine Boosters","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2021-12-06","conditions":"SARS-CoV-2","enrollment":540},{"nctId":"NCT04930770","phase":"PHASE2","title":"Study About the Response to the Administration of a Third Dose of mRNA-1273 Vaccine (COVID-19 Vaccine Moderna) in Renal Transplants With Immunological Failure Initial to Vaccination","status":"WITHDRAWN","sponsor":"Maria Joyera Rodríguez","startDate":"2021-09","conditions":"Covid19","enrollment":""},{"nctId":"NCT04796896","phase":"PHASE2, PHASE3","title":"A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2021-03-15","conditions":"SARS-CoV-2","enrollment":11942},{"nctId":"NCT05321407","phase":"","title":"COVID-19 Vaccine Responses in PIDD Subjects","status":"ACTIVE_NOT_RECRUITING","sponsor":"Duke University","startDate":"2021-09-30","conditions":"X-linked Agammaglobulinemia, XLA, Primary Immune Deficiency","enrollment":100},{"nctId":"NCT05160766","phase":"PHASE2","title":"Assessing Immune Response of Different COVID-19 Vaccines in Older Adults","status":"COMPLETED","sponsor":"Oliver Cornely, MD","startDate":"2021-11-08","conditions":"Prevention of COVID-19","enrollment":323},{"nctId":"NCT05197621","phase":"","title":"The Impact of COVID-19 on Maternal and Neonatal Outcomes","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2020-04-13","conditions":"COVID-19, Pregnancy; Infection","enrollment":300},{"nctId":"NCT05815498","phase":"PHASE3","title":"A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2023-03-28","conditions":"COVID-19","enrollment":14246},{"nctId":"NCT04889209","phase":"PHASE1, PHASE2","title":"Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-05-28","conditions":"COVID-19","enrollment":867},{"nctId":"NCT04854980","phase":"","title":"Serologic Response to the SARS-CoV-2 (COVID-19) MRNA-1273 Vaccine in Select Subsets of Oncology Patients","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2021-08-03","conditions":"Covid19, Cancer","enrollment":8},{"nctId":"NCT05280158","phase":"PHASE1, PHASE2","title":"High-Dose Moderna mRNA-1273 Booster Study for Lung Transplant Recipients","status":"TERMINATED","sponsor":"University of California, Los Angeles","startDate":"2022-03-10","conditions":"Lung Transplant Recipient, SARS-CoV-2, Immunosuppression","enrollment":19},{"nctId":"NCT06333704","phase":"","title":"Post-marketing Surveillance (PMS) Use-Result Surveillance With SPIKEVAX BIVALENT and SPIKEVAX X Injection.","status":"RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2023-03-10","conditions":"SARS-CoV-2","enrollment":4206},{"nctId":"NCT04894435","phase":"PHASE2","title":"Mix and Match of the COVID-19 Vaccine for Safety and Immunogenicity","status":"ACTIVE_NOT_RECRUITING","sponsor":"Canadian Immunization Research Network","startDate":"2021-05-20","conditions":"COVID-19","enrollment":669},{"nctId":"NCT04927065","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) Variants","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2021-05-28","conditions":"SARS-CoV-2","enrollment":5161},{"nctId":"NCT05022329","phase":"PHASE2, PHASE3","title":"COVID-19 Vaccine Boosters in Patients With CKD","status":"TERMINATED","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2021-09-30","conditions":"Chronic Kidney Diseases, COVID-19","enrollment":273},{"nctId":"NCT06130345","phase":"","title":"Post-marketing Safety of Elasomeran/Davesomeran and Andusomeran","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2023-04-14","conditions":"SARS-CoV-2","enrollment":15196685},{"nctId":"NCT05228730","phase":"PHASE3","title":"Evaluation of Full Versus Fractional Doses of COVID-19 Vaccines Given as a Booster in Adults in Australia - Mongolia, Indonesia, Australia Coronavirus (MIACoV).","status":"TERMINATED","sponsor":"Murdoch Childrens Research Institute","startDate":"2022-05-02","conditions":"COVID-19","enrollment":13},{"nctId":"NCT06441955","phase":"PHASE4","title":"Covid-19 Long Haul Preventative and Health Promotion Care Clinical Trial Acceleration Program.","status":"RECRUITING","sponsor":"Well- Konnect Healthcare Services and Research Firm","startDate":"2024-03-01","conditions":"COVID-19, Long Haul","enrollment":100},{"nctId":"NCT05501522","phase":"PHASE3","title":"Immunogenicity and Safety Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine(GBP510) Adjuvanted with AS03 in Adults Aged 18 Years and Older","status":"COMPLETED","sponsor":"SK Bioscience Co., Ltd.","startDate":"2022-12-09","conditions":"COVID-19","enrollment":840},{"nctId":"NCT05142319","phase":"PHASE4","title":"Efficacy of Different COVID-19 Vaccine Combinations in Inducing Long-term Humoral Immunity [PRIBIVAC]","status":"COMPLETED","sponsor":"Tan Tock Seng Hospital","startDate":"2021-10-12","conditions":"COVID-19","enrollment":326},{"nctId":"NCT05028257","phase":"PHASE3","title":"Allergy and COVID-19 Vaccines","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-09-15","conditions":"Anaphylactic Reaction, Vaccine Reaction","enrollment":117},{"nctId":"NCT04922944","phase":"","title":"Post COVID-19 Vaccination Analysis in Healthcare Worker Recipients","status":"COMPLETED","sponsor":"Huntington Memorial Hospital","startDate":"2021-03-08","conditions":"Covid19, Vaccine Reaction","enrollment":167},{"nctId":"NCT04847050","phase":"PHASE2","title":"A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-04-28","conditions":"Solid Tumor Malignancy, Hematologic Malignancy, Leukemia","enrollment":19},{"nctId":"NCT05249829","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Immunogenicity and Safety of Omicron Variant Vaccines in Comparison With mRNA-1273 Booster Vaccine for COVID-19","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-02-16","conditions":"SARS-CoV-2","enrollment":3548},{"nctId":"NCT05765578","phase":"","title":"An Observational Study of Moderna COVID-19 Bivalent Vaccines (Original and Omicron BA.4/BA.5) and 2023 Updated mRNA COVID-19 Vaccines (XBB.1.5)","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2023-03-08","conditions":"COVID-19","enrollment":1713},{"nctId":"NCT05016622","phase":"PHASE2","title":"Booster Dose Trial","status":"TERMINATED","sponsor":"Montefiore Medical Center","startDate":"2021-08-10","conditions":"Cancer","enrollment":106},{"nctId":"NCT04792567","phase":"PHASE4","title":"Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-04-19","conditions":"Secondary Progressive Multiple Sclerosis","enrollment":41},{"nctId":"NCT04860297","phase":"PHASE3","title":"A Study to Evaluate Safety and Immunogenicity of mRNA-1273 Vaccine to Prevent COVID-19 in Adult Organ Transplant Recipients and in Healthy Adult Participants","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2021-04-16","conditions":"SARS-CoV-2","enrollment":234},{"nctId":"NCT06429020","phase":"","title":"Sonography for COVID-19 Vaccines Related Reactive Lymphadenopathy","status":"COMPLETED","sponsor":"Chimei Medical Center","startDate":"2023-01-01","conditions":"Reactive Axillary Lymphadenopathy for SARS-CoV-2 Vaccines in the Asian Taiwanese Population","enrollment":1089},{"nctId":"NCT04715438","phase":"NA","title":"Vaccination Against COVID-19 in Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2021-01-08","conditions":"Cancer","enrollment":791},{"nctId":"NCT04969250","phase":"PHASE4","title":"Vaccination for Recovered Inpatients With COVID-19 (VATICO)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-08-25","conditions":"Covid19","enrollment":66},{"nctId":"NCT05387317","phase":"PHASE3","title":"Evaluation of COVID-19 Vaccines Given as a Booster in Healthy Adults in Indonesia (MIACoV Indonesia)","status":"WITHDRAWN","sponsor":"Murdoch Childrens Research Institute","startDate":"2024-04","conditions":"COVID-19","enrollment":""},{"nctId":"NCT05079633","phase":"PHASE4","title":"A Heterologous Prime-boost Study to Evaluate Immunogenicity and Safety of mRNA-1273 With MVC-COV1901 in Adults","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2021-09-30","conditions":"Covid19 Vaccine","enrollment":220},{"nctId":"NCT04470427","phase":"PHASE3","title":"A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2020-07-27","conditions":"SARS-CoV-2","enrollment":30415},{"nctId":"NCT05028361","phase":"PHASE4","title":"Simultaneous mRNA COVID-19 and IIV4 Vaccination Study","status":"COMPLETED","sponsor":"Duke University","startDate":"2021-10-04","conditions":"Quality of Life, Injection Site Reaction, Adverse Drug Event","enrollment":348},{"nctId":"NCT04283461","phase":"PHASE1","title":"Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-03-16","conditions":"COVID-19, COVID-19 Immunisation","enrollment":120},{"nctId":"NCT04785144","phase":"PHASE1","title":"Safety and Immunogenicity Study of a SARS-CoV-2 (COVID-19) Variant Vaccine (mRNA-1273.351) in Naïve and Previously Vaccinated Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-03-31","conditions":"COVID-19, COVID-19 Immunisation","enrollment":135},{"nctId":"NCT05543356","phase":"PHASE3","title":"COVID-19 Fourth Dose Study in Australia","status":"WITHDRAWN","sponsor":"Murdoch Childrens Research Institute","startDate":"2022-05-02","conditions":"COVID-19","enrollment":""},{"nctId":"NCT05894525","phase":"","title":"Post-Marketing Safety Study in Japan in Participants With High Risk of Severe Exacerbation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-11-15","conditions":"SARS-CoV-2","enrollment":8844},{"nctId":"NCT05894499","phase":"","title":"Post-Marketing Safety Study in Japan of Shock and Anaphylaxis After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons in at High Risk of Severe COVID-19","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-11-15","conditions":"SARS-CoV-2","enrollment":13309},{"nctId":"NCT05894590","phase":"","title":"Post-Marketing Non-Acute Safety Study in Japan After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons at High Risk of Severe COVID-19","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-11-15","conditions":"SARS-CoV-2","enrollment":13680},{"nctId":"NCT05375838","phase":"PHASE1, PHASE2","title":"A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Old","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-05-13","conditions":"SARS-CoV-2, Influenza","enrollment":550},{"nctId":"NCT05383560","phase":"PHASE2","title":"Safety and Immunogenicity of Omicron Variant-Matched Vaccine Booster in Adults","status":"COMPLETED","sponsor":"Sheba Medical Center","startDate":"2022-09-05","conditions":"COVID-19 Pandemic, Immunogenicity, SARS CoV 2 Infection","enrollment":179},{"nctId":"NCT04832932","phase":"","title":"The COVID-19 Back-to-Normal Study: Analysis of Multiple Outcomes","status":"UNKNOWN","sponsor":"Mebo Research, Inc.","startDate":"2021-01-05","conditions":"COVID-19 Vaccines","enrollment":2000},{"nctId":"NCT04805125","phase":"PHASE3","title":"Immunocompromised Swiss Cohorts Based Trial Platform","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2021-04-19","conditions":"Immunocompromised Patients","enrollment":610},{"nctId":"NCT05075538","phase":"PHASE4","title":"COVID-19: Immune Response in Patients With Cancer Undergoing mRNA Vaccination Against SARS-CoV-2","status":"TERMINATED","sponsor":"Jules Bordet Institute","startDate":"2021-12-01","conditions":"Cancer","enrollment":152},{"nctId":"NCT06189040","phase":"PHASE4","title":"Immunogenicity After COVID-19 Vaccines in Adapted Schedules","status":"COMPLETED","sponsor":"Universiteit Antwerpen","startDate":"2021-05-26","conditions":"Coronavirus Disease 2019, COVID-19","enrollment":580},{"nctId":"NCT05230953","phase":"PHASE3","title":"Fourth COVID-19 Vaccine Dose- mRNA1273","status":"UNKNOWN","sponsor":"Sheba Medical Center","startDate":"2022-01-05","conditions":"COVID-19 Pandemic","enrollment":1000},{"nctId":"NCT04958304","phase":"","title":"Moderna COVID-19 Vaccine mRNA-1273 Observational Pregnancy Outcome Study","status":"TERMINATED","sponsor":"ModernaTX, Inc.","startDate":"2021-09-01","conditions":"SARS-CoV-2","enrollment":20},{"nctId":"NCT06006858","phase":"","title":"Post Authorization Safety Study Moderna COVID-19 Primary Vaccine","status":"COMPLETED","sponsor":"PT Bio Farma","startDate":"2022-11-03","conditions":"COVID-19","enrollment":1284},{"nctId":"NCT05047770","phase":"PHASE3","title":"A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-10-07","conditions":"Herpes Zoster","enrollment":2013},{"nctId":"NCT04826770","phase":"","title":"Adaptive Immune Response to COVID-19 Vaccination","status":"UNKNOWN","sponsor":"University Medicine Greifswald","startDate":"2021-01-06","conditions":"SARS-CoV-2 Vaccination","enrollment":70},{"nctId":"NCT04811664","phase":"PHASE3","title":"A Study of SARS CoV-2 Infection and Potential Transmission in Individuals Immunized With Moderna COVID-19 Vaccine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-03-24","conditions":"SARS-CoV-2 Infection","enrollment":1923},{"nctId":"NCT04813796","phase":"PHASE1","title":"A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2021-03-11","conditions":"SARS-CoV-2","enrollment":104},{"nctId":"NCT05710289","phase":"","title":"A Blood Collection Study to Assess the Immunogenicity of Nationally Authorized Homologous COVID-19 Booster Vaccines Among Adult Vaccinees.","status":"WITHDRAWN","sponsor":"SK Bioscience Co., Ltd.","startDate":"2023-02","conditions":"COVID-19","enrollment":""},{"nctId":"NCT04958954","phase":"","title":"Post-Marketing Safety Study of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in the United States","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2021-07-07","conditions":"SARS-CoV-2","enrollment":50000000},{"nctId":"NCT05007860","phase":"","title":"Vaccine Responsiveness in Patients With Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2020-07-16","conditions":"Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","enrollment":36},{"nctId":"NCT05420077","phase":"PHASE1","title":"Safety and Immunogenicity of RVM-V001 in Healthy Individuals Previously Vaccinated With BNT162b2 and mRNA-1273","status":"TERMINATED","sponsor":"RVAC Medicines (US), Inc.","startDate":"2022-09-12","conditions":"Infectious Disease, COVID-19","enrollment":13},{"nctId":"NCT04952402","phase":"PHASE4","title":"SARS-CoV-2 Immune Responses After COVID-19 Therapy and Subsequent Vaccine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-07-09","conditions":"Covid19, SARS-CoV2 Infection","enrollment":43},{"nctId":"NCT04930055","phase":"","title":"Immune Responses in Oncology Patients to Novel Coronavirus Vaccines (IROC)","status":"TERMINATED","sponsor":"Indiana University","startDate":"2021-06-30","conditions":"Cancer","enrollment":2206},{"nctId":"NCT04677660","phase":"PHASE1, PHASE2","title":"A Study of TAK-919 in Healthy Japanese Adults (COVID-19)","status":"COMPLETED","sponsor":"Takeda","startDate":"2021-01-07","conditions":"Coronavirus Disease (COVID-19)","enrollment":200},{"nctId":"NCT05054218","phase":"","title":"COVID-19 Immunogenicity of a Third Dose of mRNA-1273 Vaccine Among Cancer Patients","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2021-09-10","conditions":"Covid19, SARS-CoV2 Infection","enrollment":336},{"nctId":"NCT04806113","phase":"PHASE3","title":"COVID-19 Vaccine in Immunosuppressed Adults With Autoimmune Diseases","status":"COMPLETED","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2021-03-11","conditions":"Covid19, Rheumatic Diseases, Rheumatoid Arthritis","enrollment":220},{"nctId":"NCT05197153","phase":"PHASE2","title":"A Study to Evaluate the Safety and Immunogenicity of Booster With AZD1222, mRNA-1273, or MVC-COV1901 Against COVID-19","status":"COMPLETED","sponsor":"Medigen Vaccine Biologics Corp.","startDate":"2022-01-22","conditions":"COVID-19 Vaccine","enrollment":804},{"nctId":"NCT05048940","phase":"PHASE3","title":"Efficacy, Safety, and Immunogenicity of Vaccine Reimmunization With a Third Homologous Versus Heterologous Dose Against COVID-19 in Patients Undergoing Solid Organ Transplantation.","status":"WITHDRAWN","sponsor":"Instituto de Investigación Marqués de Valdecilla","startDate":"2021-09-01","conditions":"Covid19","enrollment":""},{"nctId":"NCT05228912","phase":"","title":"Immunization of 7 Different Vaccines Against SARS-COV-2 Across 4 Countries.","status":"COMPLETED","sponsor":"Hospital Clinica Nova","startDate":"2021-02-26","conditions":"Vaccine Adverse Reaction, COVID-19, Vaccine Reaction","enrollment":1870},{"nctId":"NCT05175950","phase":"PHASE2","title":"Safety, Reactogenicity, and Immunogenicity Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510)","status":"UNKNOWN","sponsor":"Korea University Guro Hospital","startDate":"2022-01-24","conditions":"COVID-19 (Healthy Volunteers)","enrollment":770},{"nctId":"NCT05208983","phase":"","title":"SafeTy and Efficacy of Preventative CoVID Vaccines","status":"UNKNOWN","sponsor":"University Health Network, Toronto","startDate":"2021-05-06","conditions":"COVID-19 Virus Infection, Vaccine Response","enrollment":1286},{"nctId":"NCT04405076","phase":"PHASE2","title":"Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2020-05-29","conditions":"SARS-CoV-2","enrollment":660},{"nctId":"NCT05081271","phase":"EARLY_PHASE1","title":"COVID-19 Booster Vaccination in Persons With Multiple Sclerosis","status":"TERMINATED","sponsor":"Griffin Hospital","startDate":"2021-10-15","conditions":"Multiple Sclerosis","enrollment":10},{"nctId":"NCT05074368","phase":"NA","title":"Efficacy and Safety of Heterologous and Homologous COVID-19 Vaccination","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2021-07-06","conditions":"Healthy Adult Volunteers","enrollment":499},{"nctId":"NCT04885907","phase":"PHASE4","title":"Third Dose of Moderna COVID-19 Vaccine in Transplant Recipients","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2021-05-25","conditions":"Vaccine Response Impaired, Immune Suppression, Covid19","enrollment":120},{"nctId":"NCT05132855","phase":"PHASE1, PHASE2","title":"The Immune Response of Heterologous Boost Third Dose of mRNA and Protein COVID-19 Vaccine","status":"UNKNOWN","sponsor":"Chang Gung Memorial Hospital","startDate":"2021-11-30","conditions":"COVID-19, Breakthrough Infection","enrollment":340},{"nctId":"NCT04978038","phase":"PHASE4","title":"Fourth Dose of mRNA COVID-19 Vaccine in Residents of LTCFs","status":"UNKNOWN","sponsor":"Mark Loeb","startDate":"2022-08-01","conditions":"SARS-CoV2 Infection, Coronavirus Infection","enrollment":414}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2280,"recentPublications":[{"date":"2026 Mar 28","pmid":"41905062","title":"Transient elevation of NT-proBNP after mRNA COVID-19 vaccination in healthy adults: A longitudinal biomarker analysis.","journal":"Vaccine"},{"date":"2026 Mar 14","pmid":"41901323","title":"Incidence of Guillain-Barré Syndrome Following COVID-19 Vaccination and SARS-CoV-2 Infection: A Population-Based Cohort Study Using the Valencia Health System Integrated Database (Spain).","journal":"Pharmaceuticals (Basel, Switzerland)"},{"date":"2026 Mar 27","pmid":"41896708","title":"The COVALAC Study: The Impact of COVID-19 Vaccination During Lactation on SARS-CoV-2-Specific Antibodies in Human Milk-A Prospective Cohort Study.","journal":"Journal of human lactation : official journal of International Lactation Consultant Association"},{"date":"2026","pmid":"41859091","title":"Association of plasma ferritin and plasma iron at time of vaccination with the immune response to SARS-CoV-2 vaccination: a longitudinal cohort study.","journal":"Frontiers in immunology"},{"date":"2026 Dec","pmid":"41848549","title":"Hematologic adverse events following COVID-19 vaccination and revaccination in persons aged 12 and above: A Canadian Immunization Research Network study.","journal":"Human vaccines & immunotherapeutics"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Elasomeran","Imelasomeran","Davesomeran","Spikevax","Spikevax bivalent"],"phase":"marketed","status":"active","brandName":"mRNA-1273","genericName":"mRNA-1273","companyName":"Assistance Publique - Hôpitaux de Paris","companyId":"assistance-publique-h-pitaux-de-paris","modality":"Biologic","firstApprovalDate":"","aiSummary":"mRNA-1273 is a lipid nanoparticle-formulated messenger RNA vaccine that encodes the SARS-CoV-2 spike protein, instructing cells to produce the antigen and trigger adaptive immune responses. Used for COVID-19 prevention in adults and pediatric populations, COVID-19 booster vaccination.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":16,"withResults":10},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}